The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization dedicated to advancing cell and gene therapies, has unveiled the UK 2023 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.
According to the database, the number of ongoing ATMP clinical trials in the UK has exhibited remarkable stability over the past three years. In 2023, there were 175 trials ongoing, a slight decrease from 178 in 2022 and an increase from 168 in 2021. This stands in contrast to the global trend, where there was an approximate 10% decline in ongoing ATMP clinical trials from January to December 2023.
The CGT Catapult database highlights the UK's continued attractiveness as a destination for commercial trials, with commercial trials constituting 81% of all trials in 2023, a marginal increase from 80% in 2022.
Providing a detailed breakdown of ongoing trials in the UK, the database reveals that oncology remains the dominant therapeutic area, representing 41% of all trials. Consistent with 2022, gene therapies make up the majority of ATMP clinical trials in the UK at 76%, followed by somatic-cell therapies at 19%. This data underscores the UK's sustained appeal for a diverse range of advanced therapy clinical trials, reaffirming its position as a preferred hub for cutting-edge research in the pharmaceutical landscape.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!